Valued at a market cap of $228.3 billion, Abbott Laboratories (ABT) is a global healthcare company that discovers, develops, ...

Let’s dig into the relative performance of Abbott Laboratories (NYSE:ABT) and its peers as we unravel the now-completed Q4 ...

Abbott’s pulse field ablation system competes with products from Medtronic and Boston Scientific, which also have large ...

Abbott Laboratories closed 6.08% below its 52-week high of $141.23, which the company reached on March 4th.

Abbott Laboratories (NYSE:ABT) recently announced successful outcomes from its TRILUMINATE™ Pivotal trial for the TriClip™ system, showcasing significant improvements in patient outcomes for tricuspid ...

On Feb. 19, students from Roberts Middle School in Cuyahoga Falls, Ohio, toured R.D. Abbott's Barberton Service Center, which ...

We recently published a list of Diamond Hill Capital Stock Portfolio: Top 10 Stock Picks. In this article, we are going to ...

Johnson & Johnson and Boston Scientific have also recently made moves to sell their own coronary intravascular lithotripsy ...

Barclays analyst Matt Miksic maintained a Buy rating on Abbott Laboratories (ABT – Research Report) today and set a price target of $158.00.

Abbott (ABT) announced late-breaking data from its Triluminate Pivotal trial that show the TriClip transcatheter edge-to-edge repair system to ...

The company is first rolling out the use of the Volt system among European Union doctors who have already gained experience ...

Abbott Laboratories closed 11.07% short of its 52-week high of $141.23, which the company achieved on March 4th.